PointState Capital’s BioNTech BNTX Stock Holding History

PointState Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,908	Closed	-$1.01M	–	81
2021 Q4	$1.01M	Buy	3,908 +408	+12%	+$112K	0.02%	113
2021 Q3	$955K	Sell	3,500 -6,500	-65%	-$2.07M	0.02%	131
2021 Q2	$2.24M	Sell	10,000 -17,700	-64%	-$3.34M	0.04%	109
2021 Q1	$3.02M	Buy	27,700 +15,200	+122%	+$1.61M	0.06%	104
2020 Q4	$1.02M	Buy	+12,500	New	+$1.23M	0.02%	119

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PointState Capital's BNTX Position: Q1 2022 in Review

PointState Capital sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 3,908 shares — an estimated $1.01M sold.

PointState Capital first reported a position in BNTX in Q4 2020 and held it in 5 quarters. The position peaked at $3.02M in Q1 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

PointState Capital reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 3,908 BioNTech shares in Q1 2022, an estimated $1.01M.
PointState Capital first reported a position in BioNTech in Q4 2020 and held it in 5 quarters.
PointState Capital's BioNTech position peaked at $3.02M in Q1 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.